{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:37:39Z","timestamp":1791920259026,"version":"4.3.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Alzheimer's disease (AD) has become the primary cause of dementia. It shows a progressive cognitive dysfunction with degenerating neurons. Acetylcholine receptors (AChRs) propagate the cognitive ability and it consists of two primary members namely muscarinic (mAChRs) and nicotinic receptors (nAChRs). Where mAChRs is G-protein coupled receptor, (nAChRs) are ligand-gated ion channels. The conventional therapeutic regimen for AD consists of three acetylcholinestearse inhibitors while a single NMDA receptor antagonist. Researchers around the globe are developing new and modifying the existing AChRs agonists to develop lead candidates with lower risk to benefit ratio where benefits clearly outweigh the adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>We have searched PubMed, MEDLINE, Google scholar, Science Direct and, Web of Science with keywords \u201cMuscarinic\/Nicotinic acetylcholine receptor, agonists and, AD\u201d. The literature search included articles written in English. Scientific relevance for clinical studies, basic science studies is eligibility criteria for articles referred in this paper. M1 is the primary muscarinic subtype while \u03b17 is the primary nAChR subtype that is responsible for cognition and memory and these two have been the major recent experimental targets for mAChR agonist strategy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>The last cholinergic receptor agonist to enter phase 3 trial was EVP-6124 (Enceniclin) but was withdrawn due to severe gastrointestinal adverse effects. We aim to present an overview of the efforts and achievements in targeting Muscarinic and Nicotinic acetylcholine receptor in the current review for development of better AD therapeutics.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jphp.12919","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T01:52:31Z","timestamp":1523929951000},"page":"985-993","source":"Crossref","is-referenced-by-count":111,"title":["Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy"],"prefix":"10.1093","volume":"70","author":[{"given":"Stuti","family":"Verma","sequence":"first","affiliation":[{"name":"Department of Biotechnology, National Institute of Technology Raipur , Raipur,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, National Institute of Technology Raipur , Raipur,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timir","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, North-Eastern Hill University , Shillong,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8735-479X","authenticated-orcid":false,"given":"Awanish","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, National Institute of Technology Raipur , Raipur,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,8,1]]},"reference":[{"key":"2024103012313419000_jphp12919-cit-0001","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.dadm.2016.03.002","article-title":"Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers","volume":"3","author":"De Marshall","year":"2016","journal-title":"Alzheimers Dement (Amst)"},{"key":"2024103012313419000_jphp12919-cit-0002","doi-asserted-by":"crossref","first-page":"a006213","DOI":"10.1101\/cshperspect.a006213","article-title":"Brain imaging in Alzheimer disease","volume":"2","author":"Johnson","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2024103012313419000_jphp12919-cit-0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-7404-7_1","article-title":"Alzheimer's Disease Therapy: Present and Future Molecules","volume-title":"Computational modeling of drugs against Alzheimer's disease","author":"Kumar","year":"2018"},{"key":"2024103012313419000_jphp12919-cit-0004","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1570159X13666150716165726","article-title":"Alzheimer's disease: targeting the cholinergic system","volume":"14","author":"Ferreira-Vieira","year":"2016","journal-title":"Curr Neuropharmacol"},{"key":"2024103012313419000_jphp12919-cit-0005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12264-013-1406-z","article-title":"M1 muscarinic acetylcholine receptor in Alzheimer's disease","volume":"30","author":"Jiang","year":"2014","journal-title":"Neurosci Bull"},{"key":"2024103012313419000_jphp12919-cit-0006","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2217\/nmt.11.43","article-title":"Muscarinic receptors and Alzheimer's disease","volume":"1","author":"Avila","year":"2011","journal-title":"Neurodegen Dis Manage"},{"key":"2024103012313419000_jphp12919-cit-0007","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/157015907781695946","article-title":"Allosteric modulation of muscarinic acetylcholine receptors","volume":"5","author":"Gregory","year":"2007","journal-title":"Curr Neuropharmacol"},{"key":"2024103012313419000_jphp12919-cit-0008","first-page":"183","article-title":"Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia","volume":"10","author":"Foster","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2024103012313419000_jphp12919-cit-0009","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1124\/pr.108.000562","article-title":"Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection","volume":"61","author":"Buckingham","year":"2009","journal-title":"Pharmaol Rev"},{"key":"2024103012313419000_jphp12919-cit-0010","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.tips.2008.12.002","article-title":"Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders","volume":"30","author":"Conn","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"2024103012313419000_jphp12919-cit-0011","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1523\/JNEUROSCI.6393-09.2010","article-title":"Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo","volume":"30","author":"Davis","year":"2010","journal-title":"J Neurosci"},{"key":"2024103012313419000_jphp12919-cit-0012","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1039\/c002938f","article-title":"Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders","volume":"6","author":"Digby","year":"2010","journal-title":"Mol BioSyst"},{"key":"2024103012313419000_jphp12919-cit-0013","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbr.2009.12.049","article-title":"Developmental aspects of the cholinergic system","volume":"221","author":"Abreu-Villaca","year":"2011","journal-title":"Behav Brain Res"},{"key":"2024103012313419000_jphp12919-cit-0014","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s40263-014-0201-3","article-title":"Targeting brain \u03b17 nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status","volume":"28","author":"Vall\u00e9s","year":"2014","journal-title":"CNS Drugs"},{"key":"2024103012313419000_jphp12919-cit-0015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/bs.irn.2015.08.002","article-title":"Nicotinic cholinergic mechanisms in Alzheimer's disease","volume":"124","author":"Shen","year":"2015","journal-title":"Int Rev Neurobiol"},{"key":"2024103012313419000_jphp12919-cit-0016","doi-asserted-by":"crossref","first-page":"13434","DOI":"10.1039\/C5CC05264E","article-title":"Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer's disease","volume":"51","author":"Rajasekhar","year":"2015","journal-title":"Chem Commun (Camb)"},{"key":"2024103012313419000_jphp12919-cit-0017","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2174\/138161206775474224","article-title":"Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons","volume":"12","author":"D'Andrea","year":"2006","journal-title":"Curr Pharm Des"},{"key":"2024103012313419000_jphp12919-cit-0018","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1006\/mcne.2002.1112","article-title":"Selective nicotinic receptor consequences in APP(SWE) transgenic mice","volume":"20","author":"Bednar","year":"2002","journal-title":"Mol Cell Neurosci"},{"issue":"Pt B","key":"2024103012313419000_jphp12919-cit-0019","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neuropharm.2014.11.018","article-title":"Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment","volume":"96","author":"Lombardo","year":"2015","journal-title":"Neuropharmacology"},{"key":"2024103012313419000_jphp12919-cit-0020","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/bjp.2008.152","article-title":"Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1","volume":"154","author":"Langmead","year":"2008","journal-title":"Br J Pharmacol"},{"key":"2024103012313419000_jphp12919-cit-0021","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1021\/acs.jmedchem.5b01562","article-title":"4\u2212Phenylpyridin\u22122\u2212one derivatives: a novel class of positive allosteric modulator of M1 muscarinic acetylcholine receptor","volume":"59","author":"Mistry","year":"2016","journal-title":"J Med Chem"},{"key":"2024103012313419000_jphp12919-cit-0022","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/sj.bjp.0706780","article-title":"Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder","volume":"148","author":"Abrams","year":"2006","journal-title":"Br J Pharmacol"},{"key":"2024103012313419000_jphp12919-cit-0023","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jfma.2015.04.001","article-title":"Current and novel therapeutic molecules and targets in Alzheimer's disease","volume":"115","author":"Kumar","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"2024103012313419000_jphp12919-cit-0024","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.pharmthera.2007.09.009","article-title":"Muscarinic acetylcholine receptors as CNS drug targets","volume":"117","author":"Langmead","year":"2008","journal-title":"Pharmacol Ther"},{"key":"2024103012313419000_jphp12919-cit-0025","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1021\/acschemneuro.6b00278","article-title":"Disease-modifying effects of M1 muscarinic acetylcholine receptor activation in an Alzheimer's disease mouse model","volume":"8","author":"Lebois","year":"2017","journal-title":"ACS Chem Neurosci"},{"key":"2024103012313419000_jphp12919-cit-0026","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1124\/mol.116.104182","article-title":"Molecular mechanisms of action of M5 muscarinic acetylcholine receptor allosteric modulators","volume":"90","author":"Berizzi","year":"2016","journal-title":"Mol Pharmacol"},{"key":"2024103012313419000_jphp12919-cit-0027","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.neuropharm.2009.10.003","article-title":"AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model","volume":"58","author":"Bradley","year":"2010","journal-title":"Neuropharmacol"},{"key":"2024103012313419000_jphp12919-cit-0028","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1124\/jpet.108.140350","article-title":"Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats","volume":"327","author":"Brady","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"2024103012313419000_jphp12919-cit-0029","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1021\/jm960683m","article-title":"Design and synthesis of m1-selective muscarinic agonists: (R)-(-)-(Z)- 1-azabicyclo[2.2.1]heptan-3-one, O-(3-(3\u2019-methoxyphenyl)-2-propynyl)-oxime maleate (CI-1017), a functionally M1-selective muscarinic agonist","volume":"41","author":"Tecle","year":"1998","journal-title":"J Med Chem"},{"key":"2024103012313419000_jphp12919-cit-0030","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.trci.2016.07.001","article-title":"Alzheimer's drug-development pipeline: 2016","volume":"2","author":"Cummings","year":"2016","journal-title":"Alzheimers Dement (N Y)"},{"key":"2024103012313419000_jphp12919-cit-0031"},{"key":"2024103012313419000_jphp12919-cit-0032"},{"key":"2024103012313419000_jphp12919-cit-0033"},{"key":"2024103012313419000_jphp12919-cit-0034","doi-asserted-by":"crossref","first-page":"14271","DOI":"10.1523\/JNEUROSCI.3930-09.2009","article-title":"A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning","volume":"29","author":"Shirey","year":"2009","journal-title":"J Neurosci"},{"key":"2024103012313419000_jphp12919-cit-0035","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1039\/C4AY00102H","article-title":"Pharmacokinetics and tissue distribution of a M1 muscarinic acetylcholine receptor positive allosteric potentiator, benzyl quinolone carboxylic acid","volume":"6","author":"Khatwal","year":"2014","journal-title":"Anal Methods"},{"key":"2024103012313419000_jphp12919-cit-0036"},{"key":"2024103012313419000_jphp12919-cit-0037"},{"key":"2024103012313419000_jphp12919-cit-0038","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Arch Neurol"},{"key":"2024103012313419000_jphp12919-cit-0039"},{"key":"2024103012313419000_jphp12919-cit-0040","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00023210-199912030-00004","article-title":"Muscarinic receptor agonists in Alzheimer's disease. more than just symptomatic treatment?","volume":"12","author":"Fisher","year":"1999","journal-title":"CNS Drugs"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12919","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/70\/8\/985\/60223749\/jphp12919.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/70\/8\/985\/60223749\/jphp12919.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T17:41:16Z","timestamp":1730310076000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/70\/8\/985\/6121736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,1]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8,1]]},"published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.12919","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"value":"2042-7158","type":"electronic"},{"value":"0022-3573","type":"print"}],"subject":[],"published-other":{"date-parts":[[2018,8]]},"published":{"date-parts":[[2018,8,1]]}}}